Rhenman & Partners Asset Management Ab Intercept Pharmaceuticals, Inc. Transaction History

Rhenman & Partners Asset Management Ab

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 16, 2020	SELL	$46.7 - $92.04 $1.87 Million - $3.68 Million	-40,000 Closed	0 $0
Q4 2019 Jan 17, 2020	SELL	$57.36 - $124.1 $435,936 - $943,160	-7,600 Reduced 15.97%	40,000 $4.96 Million
Q3 2019 Oct 16, 2019	BUY	$58.69 - $80.46 $586,900 - $804,599	10,000 Added 26.6%	47,600 $3.16 Million
Q2 2019 Jul 22, 2019	BUY	$77.77 - $120.68 $2.92 Million - $4.54 Million	37,600 New	37,600 $2.99 Million
Q1 2018 Apr 11, 2018	SELL	$52.72 - $67.25 $2.03 Million - $2.59 Million	-38,500 Closed	0 $0

Q4 2017 Jan 19, 2018	SELL	$58.2 - $72.76 $87,300 - $109,140	-1,500 Reduced 3.75%	38,500 $2.25 Million
Q3 2017 Oct 13, 2017	BUY	$57.01 - $118.75 $2.28 Million - $4.75 Million	40,000	40,000 $2.32 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.